NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update


NEW YORK, March 2, Mar 02, 2015 (GLOBE NEWSWIRE via COMTEX) NeoStem, Inc. (Nasdaq:NBS) ( NeoStem or the Company ), a biopharmaceutical company developing novel, cell-based personalized medicine therapies, announced today 2014 year end results and provided an update on its business. We are pleased with our company s achievements in 2014 and look forward to reporting on our progress advancing the programs in our diversified and balanced pipeline, said Dr. David J. Mazzo, Chief Executive Officer of NeoStem. Our near-term focus will be the initiation of and continued enrollment in our Phase 3 Intus Study for stage III recurrent and stage IV metastatic melanoma patients. This is a program supported by Special Protocol Assessment as well as Fast Track and Orphan Designations. We expect the first patient randomization for the study in the second quarter of 2015. We also are planning the release of one-year data from the PreSERVE…

View original post 12 more words

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s